Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-03

AUTHORS

Thomas Reissmann, Rainer Voegeli, Jörg Pohl, Peter Hilgard

ABSTRACT

By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells. More... »

PAGES

179-184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00204986

DOI

http://dx.doi.org/10.1007/bf00204986

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025873521

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2924329


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adjuvants, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clone Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Innate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunization, Passive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Inbred BALB C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Inbred Strains", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reissmann", 
        "givenName": "Thomas", 
        "id": "sg:person.01340535776.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voegeli", 
        "givenName": "Rainer", 
        "id": "sg:person.0633453775.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633453775.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pohl", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.0750105001.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750105001.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hilgard", 
        "givenName": "Peter", 
        "id": "sg:person.01023655171.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01631649", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000151847", 
          "https://doi.org/10.1007/bf01631649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-2776(08)60685-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005456489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(85)90016-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009463786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(85)90016-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009463786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.155.1.276", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012689937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-230x(08)60846-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022578868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(86)90098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0192-0561(86)90098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026508026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031449860", 
          "https://doi.org/10.1007/bf00205685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031449860", 
          "https://doi.org/10.1007/bf00205685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/271663a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041761092", 
          "https://doi.org/10.1038/271663a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560457", 
          "https://doi.org/10.1007/bf00205549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00205549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046560457", 
          "https://doi.org/10.1007/bf00205549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/262077a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053098476", 
          "https://doi.org/10.1038/262077a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199832", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053466732", 
          "https://doi.org/10.1007/bf00199832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199832", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053466732", 
          "https://doi.org/10.1007/bf00199832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(83)90303-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053705634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-1759(83)90303-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053705634"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/18.6.769", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075788095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079465053", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079745935", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/76.4.745", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079760047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/77.6.1255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079781898"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079848326", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079909305", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080245159", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081599010", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081632263", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082078324", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082165067", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082270364", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-03", 
    "datePublishedReg": "1989-03-01", 
    "description": "By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00204986", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "name": "Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models", 
    "pagination": "179-184", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7b439e730321861869fefaaf8d770228eaa46844f7b7a07bb1718c1229821cb7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2924329"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8605732"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00204986"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025873521"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00204986", 
      "https://app.dimensions.ai/details/publication/pub.1025873521"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130829_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF00204986"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00204986'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      71 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00204986 schema:about N0747dcf5447f47309bf88f9a74e03c5a
2 N07700b142eec4251b4c9908466f6d305
3 N2d8e65011ff74f66b5be95c7aea789ab
4 N33095ab44ce442d08c021ec80b1a5af3
5 N4bafc757d3b84297bf6a45ce3a4867f2
6 N59e0d293f7294cc6a9ea7baa3fc6f017
7 N6b5cf9e99273424fb18ef1a50dc1f3e2
8 N709c9952b50a4ea2ad6ea444a03b60be
9 N86c57d4ada6c4d1894d68ceb1a7119b4
10 N8b5033227b8b47cc93b43fd8b848f47d
11 Na24091e3447249df84799172c8cd9502
12 Nb68bf2128c22409c865c7fb1053cdbd0
13 Nbd12c3e048be4da1ae3336889beecf6e
14 Nd3dc71facdf644eaa32fc6d904ec5010
15 Ndc55899d9be34d8eb004023b1b8ecd11
16 Ne15d87aa635b43c48a9ef68c26eacc1a
17 Nec96ac3331b34e6fbf22ad8426c9a79b
18 anzsrc-for:11
19 anzsrc-for:1107
20 schema:author Nb0ca55eb8b4243b5a957e155e2ecb74c
21 schema:citation sg:pub.10.1007/bf00199832
22 sg:pub.10.1007/bf00205549
23 sg:pub.10.1007/bf00205685
24 sg:pub.10.1007/bf01631649
25 sg:pub.10.1038/262077a0
26 sg:pub.10.1038/271663a0
27 https://app.dimensions.ai/details/publication/pub.1079465053
28 https://app.dimensions.ai/details/publication/pub.1079745935
29 https://app.dimensions.ai/details/publication/pub.1079848326
30 https://app.dimensions.ai/details/publication/pub.1079909305
31 https://app.dimensions.ai/details/publication/pub.1080245159
32 https://app.dimensions.ai/details/publication/pub.1081599010
33 https://app.dimensions.ai/details/publication/pub.1081632263
34 https://app.dimensions.ai/details/publication/pub.1082078324
35 https://app.dimensions.ai/details/publication/pub.1082165067
36 https://app.dimensions.ai/details/publication/pub.1082270364
37 https://doi.org/10.1016/0022-1759(83)90303-4
38 https://doi.org/10.1016/0192-0561(85)90016-5
39 https://doi.org/10.1016/0192-0561(86)90098-6
40 https://doi.org/10.1016/s0065-230x(08)60846-5
41 https://doi.org/10.1016/s0065-2776(08)60685-9
42 https://doi.org/10.1084/jem.155.1.276
43 https://doi.org/10.1093/jnci/18.6.769
44 https://doi.org/10.1093/jnci/76.4.745
45 https://doi.org/10.1093/jnci/77.6.1255
46 schema:datePublished 1989-03
47 schema:datePublishedReg 1989-03-01
48 schema:description By cloning in vitro we have obtained two sublines of the L5222 rat leukemia, one with high (L5222-S) and the other with low (L5222-R) in vivo sensitivities to non-toxic doses of mafosfamide, a stabilized derivative of 4-hydroxy-cyclophosphamide. This sensitivity in vivo was not related to the cytotoxic activity of the drug in vitro. Treatment of rats bearing the L5222-S and of mice transplanted with the MOPC-315 plasmocytoma with low doses of mafosfamide or cyclophosphamide resulted in a high percentage of surviving animals, which were resistant to a subsequent tumor challenge. Viable leukemic cells were needed to establish antitumor immunity, since it was not possible to induce resistance by injection of mitomycin-C-treated, non-viable L5222 cells. The adoptive transfer of spleen cells from animals immune against the L5222-S and the MOPC-315 resulted in resistance of the syngeneic recipients against a rechallenge with tumor cells, provided that the animals were treated with an immunosuppressive dose (100 mg/kg) of cyclophosphamide prior to the spleen cell implantation. In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically. The data presented confirm that therapy with cyclophosphamide or mafosfamide enhances host antitumor immunity but, contrary to previous reports, it could be demonstrated that successful tumor rejection was independent of T cells.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N54b64de7d6aa4ab886831ae71b0a517b
53 Nb51d0a60c1ac464e9014630d28e06f99
54 sg:journal.1096240
55 schema:name Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models
56 schema:pagination 179-184
57 schema:productId N0a3c673fc0e04b6991e3c66045a9058b
58 N170c01035a364df4bb2842ae5561ebe3
59 N2bb8e179aec5494e86eaba376b3be2a4
60 N3612e8e2779247ecbf1f43122d701f1b
61 N9b4fc7a3616747c980b29229b6ff0804
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025873521
63 https://doi.org/10.1007/bf00204986
64 schema:sdDatePublished 2019-04-11T14:00
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N5471cd3320f442adb38884f3d5858e3e
67 schema:url http://link.springer.com/10.1007%2FBF00204986
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N0747dcf5447f47309bf88f9a74e03c5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Immunity, Innate
73 rdf:type schema:DefinedTerm
74 N07700b142eec4251b4c9908466f6d305 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Male
76 rdf:type schema:DefinedTerm
77 N0a3c673fc0e04b6991e3c66045a9058b schema:name dimensions_id
78 schema:value pub.1025873521
79 rdf:type schema:PropertyValue
80 N170c01035a364df4bb2842ae5561ebe3 schema:name pubmed_id
81 schema:value 2924329
82 rdf:type schema:PropertyValue
83 N2bb8e179aec5494e86eaba376b3be2a4 schema:name readcube_id
84 schema:value 7b439e730321861869fefaaf8d770228eaa46844f7b7a07bb1718c1229821cb7
85 rdf:type schema:PropertyValue
86 N2d8e65011ff74f66b5be95c7aea789ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Rats, Inbred Strains
88 rdf:type schema:DefinedTerm
89 N33095ab44ce442d08c021ec80b1a5af3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Leukemia, Experimental
91 rdf:type schema:DefinedTerm
92 N3612e8e2779247ecbf1f43122d701f1b schema:name doi
93 schema:value 10.1007/bf00204986
94 rdf:type schema:PropertyValue
95 N3dbd0146d75b4b629931b786158293a1 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
96 rdf:type schema:Organization
97 N483544b6542d4a158864815f6cc7522e rdf:first sg:person.0750105001.98
98 rdf:rest Na830f7b61a594c3893c43e6763681b71
99 N4bafc757d3b84297bf6a45ce3a4867f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Mice, Nude
101 rdf:type schema:DefinedTerm
102 N5471cd3320f442adb38884f3d5858e3e schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N54b64de7d6aa4ab886831ae71b0a517b schema:volumeNumber 28
105 rdf:type schema:PublicationVolume
106 N59e0d293f7294cc6a9ea7baa3fc6f017 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Mice, Inbred BALB C
108 rdf:type schema:DefinedTerm
109 N6b5cf9e99273424fb18ef1a50dc1f3e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Rats
111 rdf:type schema:DefinedTerm
112 N709c9952b50a4ea2ad6ea444a03b60be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Female
114 rdf:type schema:DefinedTerm
115 N86c57d4ada6c4d1894d68ceb1a7119b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Adjuvants, Immunologic
117 rdf:type schema:DefinedTerm
118 N8b5033227b8b47cc93b43fd8b848f47d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Animals
120 rdf:type schema:DefinedTerm
121 N8d235da9d3424064b16f95b485826ac0 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
122 rdf:type schema:Organization
123 N8d2891041d4942d998069495a9b1612b schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
124 rdf:type schema:Organization
125 N8fd12cfe177e4d67985197761373f05b rdf:first sg:person.0633453775.54
126 rdf:rest N483544b6542d4a158864815f6cc7522e
127 N95322658be7447a585129b41183dd4a7 schema:name Department of Experimental Cancer Research, Asta Pharma AG, P. O. Box 14 01 29, D-4800, Bielefeld 14, FRG
128 rdf:type schema:Organization
129 N9b4fc7a3616747c980b29229b6ff0804 schema:name nlm_unique_id
130 schema:value 8605732
131 rdf:type schema:PropertyValue
132 Na24091e3447249df84799172c8cd9502 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antigens, Neoplasm
134 rdf:type schema:DefinedTerm
135 Na830f7b61a594c3893c43e6763681b71 rdf:first sg:person.01023655171.21
136 rdf:rest rdf:nil
137 Nb0ca55eb8b4243b5a957e155e2ecb74c rdf:first sg:person.01340535776.53
138 rdf:rest N8fd12cfe177e4d67985197761373f05b
139 Nb51d0a60c1ac464e9014630d28e06f99 schema:issueNumber 3
140 rdf:type schema:PublicationIssue
141 Nb68bf2128c22409c865c7fb1053cdbd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Clone Cells
143 rdf:type schema:DefinedTerm
144 Nbd12c3e048be4da1ae3336889beecf6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Neoplasm Transplantation
146 rdf:type schema:DefinedTerm
147 Nd3dc71facdf644eaa32fc6d904ec5010 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Mice
149 rdf:type schema:DefinedTerm
150 Ndc55899d9be34d8eb004023b1b8ecd11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Cyclophosphamide
152 rdf:type schema:DefinedTerm
153 Ne15d87aa635b43c48a9ef68c26eacc1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Immunization, Passive
155 rdf:type schema:DefinedTerm
156 Nec96ac3331b34e6fbf22ad8426c9a79b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Drug Administration Schedule
158 rdf:type schema:DefinedTerm
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
163 schema:name Immunology
164 rdf:type schema:DefinedTerm
165 sg:journal.1096240 schema:issn 0340-7004
166 1432-0851
167 schema:name Cancer Immunology, Immunotherapy
168 rdf:type schema:Periodical
169 sg:person.01023655171.21 schema:affiliation N8d2891041d4942d998069495a9b1612b
170 schema:familyName Hilgard
171 schema:givenName Peter
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023655171.21
173 rdf:type schema:Person
174 sg:person.01340535776.53 schema:affiliation N95322658be7447a585129b41183dd4a7
175 schema:familyName Reissmann
176 schema:givenName Thomas
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340535776.53
178 rdf:type schema:Person
179 sg:person.0633453775.54 schema:affiliation N3dbd0146d75b4b629931b786158293a1
180 schema:familyName Voegeli
181 schema:givenName Rainer
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633453775.54
183 rdf:type schema:Person
184 sg:person.0750105001.98 schema:affiliation N8d235da9d3424064b16f95b485826ac0
185 schema:familyName Pohl
186 schema:givenName Jörg
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750105001.98
188 rdf:type schema:Person
189 sg:pub.10.1007/bf00199832 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053466732
190 https://doi.org/10.1007/bf00199832
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/bf00205549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046560457
193 https://doi.org/10.1007/bf00205549
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/bf00205685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031449860
196 https://doi.org/10.1007/bf00205685
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/bf01631649 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000151847
199 https://doi.org/10.1007/bf01631649
200 rdf:type schema:CreativeWork
201 sg:pub.10.1038/262077a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053098476
202 https://doi.org/10.1038/262077a0
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/271663a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041761092
205 https://doi.org/10.1038/271663a0
206 rdf:type schema:CreativeWork
207 https://app.dimensions.ai/details/publication/pub.1079465053 schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1079745935 schema:CreativeWork
209 https://app.dimensions.ai/details/publication/pub.1079848326 schema:CreativeWork
210 https://app.dimensions.ai/details/publication/pub.1079909305 schema:CreativeWork
211 https://app.dimensions.ai/details/publication/pub.1080245159 schema:CreativeWork
212 https://app.dimensions.ai/details/publication/pub.1081599010 schema:CreativeWork
213 https://app.dimensions.ai/details/publication/pub.1081632263 schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1082078324 schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1082165067 schema:CreativeWork
216 https://app.dimensions.ai/details/publication/pub.1082270364 schema:CreativeWork
217 https://doi.org/10.1016/0022-1759(83)90303-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053705634
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/0192-0561(85)90016-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009463786
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/0192-0561(86)90098-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026508026
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/s0065-230x(08)60846-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022578868
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/s0065-2776(08)60685-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005456489
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1084/jem.155.1.276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012689937
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1093/jnci/18.6.769 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075788095
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/jnci/76.4.745 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079760047
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1093/jnci/77.6.1255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079781898
234 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...